Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Other Accumulated Expenses (2021 - 2025)

Roivant Sciences (ROIV) has disclosed Other Accumulated Expenses for 5 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses fell 83.45% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Sep 2025, down 83.45%, and an annual FY2025 reading of $14.6 million, down 71.33% over the prior year.
  • Other Accumulated Expenses was $1.5 million for Q3 2025 at Roivant Sciences, down from $12.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $72.6 million in Q3 2023 and bottomed at $1.5 million in Q3 2025.
  • Average Other Accumulated Expenses over 5 years is $23.6 million, with a median of $14.6 million recorded in 2025.
  • The sharpest move saw Other Accumulated Expenses surged 1940.32% in 2022, then crashed 87.7% in 2024.
  • Year by year, Other Accumulated Expenses stood at $12.4 million in 2021, then soared by 173.87% to $34.1 million in 2022, then plummeted by 40.37% to $20.3 million in 2023, then plummeted by 56.07% to $8.9 million in 2024, then plummeted by 83.45% to $1.5 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for ROIV at $1.5 million in Q3 2025, $12.4 million in Q2 2025, and $14.6 million in Q1 2025.